Latham & Watkins Advises Scientia Vascular in US$550 Million Acquisition by Medtronic

Medtronic announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across the neurovascular portfolio. The acquisition is valued at US$550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition. The acquisition is expected to close in the first half of FY27, subject to regulatory approvals and satisfaction of other closing conditions.

Latham & Watkins LLP represents Scientia Vascular in the transaction with a corporate deal team led by Boston partners Hans Brigham and Julie Scallen, and Boston counsel Stefanie Vincent, with associates Kelsey Kitchens, Cherrie Wang, and Emily Teems. Advice was also provided on tax matters by Bay Area partner Katharine Moir, with associate Jeremiah Cowen; on benefits matters by Boston partner Josh Friedman, with associate Rebecca Fishbein; on intellectual property matters by New York counsel Eliot Choy, with associate Patrick Chew; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler, with associate Chad Leiper; on FDA matters by Washington, D.C. counsel Chad Jennings; on healthcare regulatory matters by Bay Area partner Betty Pang; on antitrust matters by Washington, D.C. partners Mandy Reeves and Patrick English, with associate William Reed; on ex-US antitrust matters by Brussels partner Hector Armengod, with associate Juan Pablo Donado Diez; and on insurance matters by Los Angeles partner Harrison White.